Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006 May:113 Suppl 1:22-6.
doi: 10.1111/j.1471-0528.2006.00880.x.

Safety and tolerability of duloxetine in women with stress urinary incontinence

Affiliations
Review

Safety and tolerability of duloxetine in women with stress urinary incontinence

M Oelke et al. BJOG. 2006 May.

Abstract

Background: The serotonin/noradrenaline uptake inhibitor duloxetine has been shown to be effective in the medical treatment of stress urinary incontinence (SUI) in women.

Aim: To review the safety and tolerability of duloxetine with SUI.

Methods: A systematic Medline search for the key word "duloxetine" was performed, and abstracts from recent international gynaecological and urological meetings were also considered.

Results: Various unpleasant adverse effects exist, among which nausea is the most frequent, but is mild to moderate and transient in most cases. Dose escalation upon initiation of treatment improves the tolerability of duloxetine. The use of duloxetine appears safe as it lacks the cardiovascular adverse effects of older amine reuptake inhibitors.

Conclusions: Duloxetine has an acceptable safety profile. Dose escalation combined with patient counselling on the intensity and transient nature of adverse effects may help to further improve the benefit/tolerability ratio of duloxetine in the treatment of SUI.

PubMed Disclaimer

Similar articles

Cited by

MeSH terms

LinkOut - more resources